Skip to Main Content

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Conditions

Larynx | Lip, Oral Cavity and Pharynx

Phase II

What is the purpose of this trial?

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.

  • Trial with
    Celldex Therapeutics Inc. (Subsidiary of Medarex, Inc.)
  • Start Date
    12/01/2019
  • End Date
    11/30/2019
Trial Image

For more information about this study, contact:

Alexandra Minnella

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/04/2019
  • Study HIC
    #2000023823